Search
GenScript
Durvalumab Monoclonal Antibody (4B5)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
图: 1 / 2
Durvalumab Antibody (A02030-40) in ELISA
Standard curve of Duralumab Sandwich ELISA. The Duralumab Sandwich ELISA assay is developed by using Anti-Duralumab Antibody (7B6), mAb, Mouse (GenScript, A02029-40) and Anti-Duralumab Antibody (4B5), mAb, Mouse (GenScript, A02030-40) as the capture and detection antibodies, respectively. In this ELISA assay, Anti-Duralumab Antibody (4B5), mAb, Mouse (GenScript, A02030-40) was labeled with Biotin. GenScript can provide customized conjugation services for this product per the customer's request. The Sensitivity of detecting Duralumab is up ... View More
产品信息
A02030-40
产品规格
宿主/亚型
Mouse
/ IgG1, kappa
分类
Monoclonal
类型
Antibody
克隆号
4B5
抗原
Durvalumab
偶联物
Unconjugated
Unconjugated
Unconjugated
形式
Lyophilized
规格
40 µg
保存条件
-20°C or -80°C if preferred
运输条件
Wet ice
产品详细信息
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Durvalumab with trade name Imfinzi, is an FDA-approved anti-cancer drug. It is known as a checkpoint inhibitor drug, developed by Medimmune/AstraZeneca. Durvalumab is a human IgG1kappa monoclonal antibody. It blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).Anti-Durvalumab Antibody (4B5), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Durvalumab.
靶标信息
Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation. Thus, PD-L1 might play an important role in tumor immune evasion.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
